<DOC>
	<DOCNO>NCT02786836</DOCNO>
	<brief_summary>The ALF-MBT protocol multicenter , open label , non-randomized study determine value Breath Identification® ( BreathID® ) Acute Liver Failure 13C-Methacetin Breath Test System predict outcome patient diagnose acute liver failure meet inclusion/exclusion criterion . Up 200 evaluable patient enrol . An evaluable patient one complete one breath test least 30 minute administration 13C-Methacetin solution ( test substrate ) . The Breath Test perform patient upon admission study ( Day 1 ) repeat Days 2 , 3 , 5 7 provide contra-indications present . Each test continuously measure change metabolism 13C-Methacetin order ass improvement deterioration liver metabolic function improvement deterioration liver metabolic function . Patients contact Day 21 follow ( 21 day enrollment trial ) determine spontaneous survival , transplantation occurrence serious adverse event since patient 's last study treatment .</brief_summary>
	<brief_title>13C-Methacetin Breath Test Prediction Outcome ALF</brief_title>
	<detailed_description>The importance identify patient ALF likely die without liver transplant overstate remain primary focus clinical investigation 25 year . Traditional score system prognostic model , King 's College Criteria ( KCC ) , Sequential Organ Failure Assessment ( SOFA ) Acute Physiology Chronic Health Evaluation II ( APACHE II ) , currently use monitor patient ALF lack individual sensitivity specificity provide direct information liver 's metabolic function , key variable assess liver status potential disease progression versus recovery ALF patient . Despite recent advance use ALFSG Prognostic Index ( ALFSG-PI ) Model End-Stage Liver Disease ( MELD ) , well predictive modality still need . The 13C-Methacetin breath test rapid , reproducible , point-of-care test liver metabolic function . After oral nasogastric tube administration , 13C label Methacetin O-demethylated cytochrome P4501A2 liver biotransformed 13CO2 , expire breath . The BreathID® MCS device capture quantifies expire 13CO2 standardizes recovery expire 12CO2 nasal cannula ( conscious patient ) adaptor connect ventilator line ( intubated patient ) . The result obtain device express delta baseline ( DOB ) , express change 13CO2/12CO2 ratio comparison baseline measurement . It transform percentage 13C dose recover time ( PDR ) ingestion Methacetin , cumulative PDR ( CPRD ) , rate 13C substrate metabolize , derive breath 13C/12C ratio . This multicenter , open label , non-randomized study ALF-MBT ass functional trend liver metabolism patient diagnose ALF . Up 200 evaluable male female patient acute liver failure present time enrollment ALFSG Registry consecutively enrol . An evaluable patient one complete one ALF-MBTs measure minimum 30 ( ideally 60 ) minute administration 13C-Methacetin . Study sit include 12 clinical site locate United States involve Acute Liver Failure Study Group . The ALF-MBT perform patient upon admission study ( Day 1 ) repeat Days 2 , 3 , 5 7 , close time day possible ( within ± 4 hour ) , provide contra-indications present . Subjects contact Day 21 follow ( 21 day subject 's enrollment trial ) determine spontaneous survival , transplantation occurrence serious adverse event since subject 's last study treatment .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Adult men woman ( 1870 year age ) 2 . Severe acute liver injury 3 . INR ≥1.5 4 . Presence degree hepatic encephalopathy 5 . Duration illness &lt; 26 week 6 . Enrolled ALFSG Registry . 7 . Written informed consent patient patient 's legally authorize representative family member define Federal Register Number 21CFR50.3 ( ) 1 . Evidence preexist chronic liver disease 2 . Preexisting New York Heart Association stage III/IV heart failure 3 . Evidence preexist chronic renal failure 4 . Chronic hemodialysis prior hospital admission ALF 5 . Evidence cirrhosis ( unless clinically acute Wilson disease autoimmune ALF ) 6 . Severe obstructive lung disease ( FEV1 &lt; 50 % predict previous spirometry ) 7 . Severe shock , define mean arterial pressure ( MAP ) &lt; 70 mmHg despite &gt; 15 µg/kg/min dopamine , &gt; 0.1 µg/kg/min epinephrine , &gt; 0.1 norepinephrine µg/kg/min 8 . Extensive small bowel resection ( &gt; 50 cm ) 9 . Any evidence upper GI bleeding enrollment 10 . Liver transplantation ( LT ) prior enrollment . ( Note : Listing LT preclude participation trial . ) 11 . Pregnancy breastfeed woman ( Note : Pregnancy relate ALF may consider entry follow delivery baby assume mother wish breastfeed collect breast milk study period . ) 12 . Allergic acetaminophen ( Tylenol® acetaminophencontaining medication ) 13 . Participation clinical study evaluate experimental treatment procedure ( i.e. , enrollment ornithine phenyl acetate ( OPA ) Study ( call STOPALF ) preclude enrollment ALFMBT Study ) ( Note : Participation observatory study exclusion . ) 14 . Patients enteral drug fluid contraindicate patient either appropriately place naso/orogastric tube situ tolerate take drug preparation orally ( 200 ml ) 15 . ALF due BuddChiari Syndrome 16 . ALF cause malignancy 17 . ALF cause know suspected herpes simplex virus require acyclovir therapy 18 . Moderate severe adult respiratory distress syndrome ( ARDS ) , define Berlin Criteria ALFMBT manual procedure ( MOP ) . 19 . Subjects receive amiodarone 3hydroxy3methylglutaryl ( HMG ) Coenzyme A ( CoA ) reductase ( Statin ) drug 30 day prior study enrollment 20 . Consumption food beverage contain caffeine 24 hour prior enrollment 21 . Consumption follow drug may interfere metabolism 13CMethacetin 48 hour prior study enrollment include : Acyclovir , allopurinol , carbamazepine , cimetidine , ciprofloxacin , daidzein , disulfiram , Echinacea , enoxacin , famotidine , fluvoxamine , methoxsalen , mexiletine , montelukast , norfloxacin , phenylpropanolamine , phenytoin , propafenone , rifampin , terbinafine , ticlopidine , thiabendazole , verapamil , zileuton oral contraceptive 22 . Consumption alcohol 24 hour prior enrollment 23 . Smoking cigarette 8 hour prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>acute liver failure</keyword>
	<keyword>methacetin</keyword>
	<keyword>breath test</keyword>
	<keyword>severe acute liver injury</keyword>
	<keyword>hepatic encephalopathy</keyword>
	<keyword>ALFSG Registry</keyword>
	<keyword>acetaminophen toxicity</keyword>
</DOC>